Matthew L. Sherman - Dec 15, 2021 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
EVP & Chief Medical Officer
Signature
/s/ Jeffrey Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Dec 15, 2021
Transactions value $
$0
Form type
4
Date filed
12/17/2021, 03:05 PM
Previous filing
Oct 6, 2021
Next filing
Jan 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +11.1K +24.04% $0.00 57.3K Dec 15, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +82.3K $0.00 82.3K Dec 15, 2021 Common Stock 82.3K $9.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 11,100 Restricted Stock Units ("RSUs") under the Issuer's 2017 Stock Option and Incentive Plan (the "2017 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Includes 145 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 12, 2021.
F3 This stock option was issued pursuant to the 2017 Plan. The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date.